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ABSTRACT
Objective: This study assessed the macro level effects of multiple and varied forms

of clinical guidance for medication based treatment for heart failure. Drug mention
rates for physician visits by patients with heart failure were evaluated with respect
to the dates of publication of large randomized trial evidence and guidelines.
Design: Retrospective, cross-sectional series study
Methods: We used the National Ambulatory Medical Care Survey (NAMCS) for

years 1993-2000, which captures a probability sample of visits to United States
physicians to provide national estimates. We examined heart failure coded visit
drug mentions alongside research published during the same period to examine
trends in medication prescribing and the aggregate influence of the dissemination
of research findings. Multi year estimation equations from the National Center for
Health Statistics (NCHS) were used for calculation of sampling error.
Measurements: Medication mention rates were calculated for four sequential two-

year periods. Relative standard errors (RSEs) were generated for measuring
reliability and stability of our findings of changes in medication mention rates for
beta blockers, angiotensin converting enzyme inhibitors, spironolactone, and
angiotensin receptor blockers. Stratification and logistic regression models were
used to provide insight into other possible predictors.
Results: The number of visits by a patient with heart failure to physicians was not

statistically significantly different across the eight years of interest. The estimated
medication mention rate of beta blockers, spironolactone, and angiotensin receptor
blockers increased dramatically, but the number and rate of mentions was too low
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for statistical reliability. There was an adequate number of drug mentions of
angiotensin converting enzyme inhibitors for reliable aggregate estimates, but there
were not adequate numbers of mentions to demonstrate statistically significant
increases over the eight years. Logistic regression models showed strong
associations between increased drug mentions and later two year periods. This
association was demonstrated by progressively larger odds ratios (ORs) for
subsequent periods when the first two year period is used as a referent baseline.

Discussion: The increases in medication mention rates for all medications
corresponded with the findings of the major trials and evidence which we assessed.
The NAM CS sample size and the low percent of drug mentions in the given
therapeutic categories resulted in a lack of statistical power for determining
statistical significance of the changes in medication mention rate.

Conclusion: We conclude from our collected information, and statistical analyses
that the NAM CS demonstrated marked trends, but this study was inadequately
powered to establish statistical significance.
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MEDICATION PRESCRIBING IN HEART FAILURE: TRENDS IN DRUG
TREATMENT AND EVIDENCE FROM THE PAST TEN YEARS

INTRODUCTION

The Institute of Medicine's 2001 report, Crossing the Quality Chasm,
focused attention on the high level of unexplained variation in medical practice
quality. Geographic variance, inter-provider inconsistencies, and gaps in quality
highlighted the need for rational treatment. This effort for rational treatment has
resulted in a major movement in the medical community to align the practice of
medicine to methodically developed best practices. This broad movement is called
'Evidence Based Medicine.'
Evidence Based Medicine relies on appropriate and well-conducted
studies[ 1]. After research results are generated, this information must be
effectively disseminated to practitioners[l]. Lastly, this information must be
appropriately incorporated into the medical practitioner's daily work[2]. The
current healthcare system suffers from flaws at each of these stages. There are
unanswered questions due to a lack of high quality studies. Distribution of
knowledge is also difficult[3]. The current rate of nearly 10,000 trials annually[ 4]
creates an enormous burden on our current information dissemination system.
Congestive Heart Failure (CHF) provides a useful subject for the
investigation of the impact of evidence-based medicine for two primary reasons.
The prevalence, incidence, and burden of CHF have a substantial impact on the
U.S. health and healthcare. CHF affects 2-4.8 million people in the United
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States[5, 6]. It has an incidence of 400,000-700,000 new cases each year, and is
the leading cause of hospitalization[6]. O ' Connell and Bristow estimated the
U .S. 's total direct healthcare costs in 1991 for heart failure treatment to be $38.1
billion or 5.4% of 1991 ' s total U.S. healthcare expenditure[?] . These substantial
direct healthcare costs fail to capture the substantial societal costs that are attributed
to heart failure's mortality and disability. This large medical burden also creates an
availability of data due to the number of medical encounters recorded.
The second reason for the selection of CHF for evaluation of the impact of
evidence on practice is the numerous changes in recommendations for drug
treatment in recent years. Changes in our understanding of CHF have occurred
frequently since the 1940's, and the subsequent evolution ofrecommended
pharmacological interventions in the past decade are of particular interest. This
could not be more clearly illustrated than the case of beta-blockers that, years ago,
would be contraindicated treatment, and now are considered a cornerstone of
therapy for this condition [8, 9] .
This research is closely related to a broad group of guideline and research
implementation studies. In 2000, Jones et al. expressed the need for "complex
interventions (to be) assessed en bloc rather than trying to disentangle the effects of
individual components of guidance ... "[ 1O] It is in the spirit of this astute
observation in which this research is based. By placing emphasis on the search for
the aggregate changes in medication prescribing, alongside an extensive summary
of the published evidence during the period, a more complete picture can be
captured.
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While several guideline implementation focused studies address the
prescribing rates of Angiotensin Converting Enzyme Inhibitors (ACEis) [11-16] in
heart failure, there is a lack of studies addressing the other medications with
favorable supporting mortality studies. Recent studies and guidelines clearly make
the case for the utilization of beta blockers, spironolactone, and Angiotensin
Receptor Blockers (ARBs) depending on the type of heart failure. The association
between these published findings and guidelines and medication prescribing is the
primary focus of this investigation. This study examined national trends in
medication prescribing rates of beta blockers, ACEis, spironolactone, and ARBs.
These changes were exhibited alongside the studies and guidelines which were
expected to influence prescribing. This study also identified and tested possible
demographic and medical predictors of drug mentions in the ambulatory setting for
relevance to prescribing of these medications.
Our hypothesis was that we would see increases in drug mentions in the
immediate and subsequent two year periods of published large trial evidence which
demonstrated mortality or hospitalization benefits. We also hypothesized that
guidelines would have a similar impact by magnifying previous findings.

3

METHODS

This study is a retrospective analysis of a series of cross sectional studies
assessed in parallel with a comprehensive review of the most influential published
research.
Data source

We utilized the National Ambulatory Medical Care Survey (NAMCS),
using years 1993-2000 to examine changes in prescribing patterns. The NAMCS is
a publicly available national probability sample survey frequently used by various
leading epidemiological researchers. The study, which captures information on
visits to office-based physicians, has been performed annually since 1989 (and
sporadically prior). The survey instrument is reviewed and slightly altered every
other year, causing minor changes in content and coding. The NAMCS is well
described as a series of cross-sectional studies with visits to physicians as the unit
of measure in the survey. The complex sample design is segmented into three
stages. The first stage selects primary sampling units (PSUs), which consist of
counties, groups of counties or equivalent areas. The second stage involves
selection of physicians within the selected PSUs. Participating physicians are
randomly selected from master lists maintained by the American Medical
Association (AMA) and the American Osteopathic Association (AOA). From the
selected physicians, the group of participants is limited to non-federally employed
practitioners, and excludes the specialties of anesthesiology, radiology, and
pathology. This selection comprises the in-scope number of physicians by year
presented in table 1-1.
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In the third stage, in-scope physicians are randomly assigned to varying
one-week reporting intervals. Trained personnel provide physicians or their
designee instructions on proper survey procedures and are provided the appropriate
materials prior to the initiation of data collection. During this selected week, the
practitioners complete a survey form for a random sample of approximately 30
visits. Visits to nurse practitioners, physician's assistants and other non-physician
prescribers are not captured by this survey.
The number of in-scope selected physicians and the yearly response rates
are presented in Table 1-1. Further details on the NAMCS sample design are
available from published reports[l 7] or from the National Center for Health
Statistics' (NCHS) website. To produce more stable and reliable estimates, two
years of data were combined to produce each of our four periods of interest.
Sample
NAMCS databases for the corresponding years were limited to patients with
an International Classification of Diseases revision 9 (ICD-9) code indicating CHF.
The relevant ICD-9 codes used to identify CHF visits, as well as pertinent
comorbidities are located on table 1-2. Under this disease-based sub-sample,
additional data on diagnosis, treatment, and demographics were utilized for
analysis.
Outcome
The NAMCS attempts to capture all current medication therapy occurring
during the visit. Instruction on survey completion directs that all new or continued
medications should be recorded on the survey form. The survey allowed for the
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documentation of five (1993-94) or six (1995-2000) medications, which are
referred to as drug mentions. The drug mention rate for CHF related medications
was our surrogate outcome measure for the prescribing rate. Evaluation of the
appropriateness of drug mentions was not be made in this study. The visit data
found in the NAM CS can not be used to extrapolate the rate of drug usage by
patient.

Analysis
Articles reviewing medication treatments for CHF were utilized to identify
relevant therapeutic medication categories. Specific drug entities were identified
using a comprehensive list of medications prescribed to CHF patients during the
selected years. Medications that matched the previously identified therapeutic
categories were recorded without regard to Food and Drug Administration (FDA)
indications of individual agents. All medications recorded in the NAM CS survey
were manually reviewed for inclusion as a second check to ensure that all
medications used for CHF were identified. This list of relevant medications
appears in table 1-3. This medication list was converted to the coding system
developed by the NCHS, which is used by the NAM CS. Details on the collection
and coding of this drug information by the NCHS are available.[18] Combination
products, those with multiple active ingredients in one dosage form, were omitted
after a preliminary analysis demonstrated that all such products accounted for very
few drug mentions, and a small percent of all CHF drug mentions. Early analyses
demonstrated that a majority of these medications were combinations of two
diuretics, a common type of medication for symptomatic relief in CHF.
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This study adopted the standards of the NCHS, which does not publish
statistics on samples that are of insufficient size to rely on the central limit theorem,
which states that samples of sufficient size (30 or more), approximate the value
which would be found in the entire population. The NCHS utilizes relative
standard errors (RSEs) to measure the reliability and precision of their sample's
weighted national estimates. The RSE captures the degree sampling variability and
nonsystematic biases present in the sample. NAMCS reports approximate the RSE
through the use of first order Taylor approximations using SUDAAN (previously
an abbreviation for Survey Data Analysis, which is no longer used as a title)
statistical software. Further information on SUDAAN statistical software, which is
specialized in the analysis of clustered data, is available[l9]. Less precise methods
for approximations ofRSE for single years are published with the NAMCS
advance data reports. Equations for approximation across multiple years were
obtained directly from NCHS, and are located in Appendix A and B. These
methods use the least reliable year being aggregated to calculate RSEs for the
larger group of samples.

Predictor selection
_P reliminary predictors of drug mentions were selected from among the
demographic variables collected by the NAMCS. The patient's recorded sex, age,
race, payment type, and comorbidities expected to influence the prescribing of the
therapeutic drug categories were chosen for analysis. Age was recoded to those
less than sixty, sixty to sixty-nine, seventy to seventy-nine, and eighty and older.
Race was recoded to a dichotomous white and nonwhite variable due to insufficient
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visits for further breakdown. Visit payment coding by the NAM CS in periods 1
and 2 allowed for multiple visit payments to be captured. Beginning in period 3,
the survey form requested a single entry of only the primary expected payment.
Due to this change, this information could not be recoded without substantial
ambiguity in interpretation of this variable, therefore this information appears only
on table 1-4 and was not included in further analysis. Health Maintenance
Organization (HMO) status in periods 1 and 2 did not allow for the coding of blank
or unknown HMO status. HMO status underwent no transformation, and therefore
all blank and unknown entries in this variable appear in periods 3 and 4. Due to
this variable change, HMO status was omitted from the logistic regression analysis.
The presence of diabetes, asthma, or hypertension would be expected to
influence the rate of prescribing of medication in several of the therapeutic classes.
Beta blockers would be expected to be prescribed less :frequently in diabetics and
asthmatics, and more :frequent in hypertensive patients. ACE inhibitors would be
expected to be prescribed at higher rates in diabetics. For this reason, visits
involving these conditions as well as heart failure were also identified. Due to the
limited number of asthmatics captured by the sample, these visits were not
analyzed further.
Descriptive analyses were performed using Statistical Package for the
Social Science (SPSS version 10.0 for Windows). Each visit record was flagged
for drug mentions of relevant medications that affect heart failure mortality or
hospitalization. These records were weighted to produce national estimates, using
visit weighting by the NCHS in the NAM CS data files. These weightings take into
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account the complex multi stage probability procedure and adjust for nonresponse.
A weighting adjustment is also made for the physician to population ratio.
Beginning in 1995, a weight smoothing technique was utilized in these weightings
as well.[20] These visit based rates were considered in parallel with the published
studies, as well as their statistical stability and reliability.
A list of published studies of medication usage with hospitalization or
mortality outcome measures and treatment guidelines in heart failure was
generated. The focus was on the larger studies which individually influenced the
current standards and guidelines. This clinical trial list, organized by publication
dates and medication therapeutic category, was utilized to watch for changes in
practice patterns. This list descriptively outlined the outcome measure used, and
the direction of the findings . Review articles, although likely influential in the
aggregate, were not included due to the difficulty in determining completeness and
interpretability. Guidelines that were not generally published or disseminated
extensively, such as those by the American Medical Directors Association, were
also excluded. These lists, by therapeutic classification, populate tables 2-1, 3-1, 41, and 5-1.
In measuring the degree of statistical significance and precision in our
estimates, RSEs were chosen in preference to confidence intervals (CD or statistical
tests since RSEs are the standard method utilized within the NCHS for the
NAMCS, providing for a "gold standard" for this type ofresearch. Calculations of
RSE were made according to previously unpublished multi-year estimate
equations, which are available from the NCHS, or in the appendix of this thesis.
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The complex sampling methods utilized in the NAMCS requires the calculation of
cell sizes and RSEs to ensure a stable and precise estimate. The RSE can be
translated to a confidence interval by multiplying the RSE by the estimate to obtain
the standard error. There is a 95% confidence that the true value lies within twice
the standard error of the value produced by the NAMCS, with the caveat that RSEs
greater than 30% are considered unreliable by the NCHS definition.
Two different methods were utilized to assess and control for other possible
influences on the drug mention rate. The first method consisted of stratification of
the cases into subgroups and outcomes. This simple method was valuable for
accessing the importance of individual predictors in isolation. The stratified
analysis assessed the percentage of drug mentions by age, sex, race, diabetic status,
and hypertensive status. The stratified analysis also listed the percent of drug
mentions by those which were and were not related to an HMO. The stratified
percentages on HMO status excluded those reporting blank or unknown in periods
3 and 4. These were excluded from the table to minimize potential confusion, and
because a blank or unknown coding does not have a conceptual association with
outcomes of interest.
The second method to control for other predictors was a multivariate
standard logistic regression model to appraise the differing impact of the many
suspected predictors simultaneously. In this multivariate analysis, period was our
proxy measure for the impact of the evidence when in agreement with the timing
and direction of the various findings. Odds ratios (OR) were used to assess each
predictor's impact on prescribing where the odds of the referent category is set to 1.
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An OR> 1 indicates an increased association between the outcome of drug mention

and the listed characteristic, while an OR<l indicates a decreased association. Our
confidence intervals represent the range that we are 95% statistically confident that
our true values would fall within.
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RESULTS

Limiting the records to those with a diagnosis of heart failure by the ICD-9
code listed on table 1-2 returned 1725 unweighted records for the four periods of
analysis. After weighting, these surveys approximated 47 million visits over eight
years. The number of visits over the four two-year periods remained relatively
stable as shown on table 1-5, ranging from a high of 12.3 million in period 1 to a
low of 11.2 million visits in period 3. The confidence intervals for all four periods
overlap, demonstrating a lack of statistically significant difference.
Demographics of the visits are detailed on table 1-4. The sex of patients
visiting for CHF was approximately evenly split with female visits in a slight
majority (51.9%). Older individuals accounted for more visits than younger
patients, with age 80 or older individuals accounting for the largest number of
visits. Whites accounted for a majority of the visits (87.3%) as compared to nonwhites. Diabetic patients comprised 14% of the sample, while asthmatics
comprised only 1.3% of the estimated national visits for CHF. Hypertension was
coded for the visits 18% of the time, but may have been omitted from coding more
frequently if those recording information considered it less relevant in the light of a
CHF coding. Recoded payment indicates a large number of Medicaid visits
(55.3%) and blank or unknown status (22.8%), which likely resulted from the
recoding of multi-coded payments from earlier periods to a status of "unknown".
Beta blockers

Beta blocker drug mentions were found to increase steadily and
incrementally through the four periods, from 0.4 million mentions in period 1, to
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1.6 million mentions in period 4. These estimates must be interpreted cautiously as
the RSEs for all four periods exceed the 30% cutoff for stable and precise estimates
as defined by the NCHS.
Large mortality and hospitalization studies during the four periods for beta
blocker usage in heart failure were numerous, as were guidelines, as listed on table
2-1. In period 1, the Cardiac Insufficiency Bisoprolol Study (CIBIS) study was
published, which was the first large trial to evaluate the impact of beta blockers on
CHF mortality and hospitalization. Period 2 brought a set of trials in the US
Carvedilol Heart Failure Trials Program, which consisted of five total publications.
Three of the studies in the program, which measured mortality, as well as the
published report that summarized them, appear on the table. The last of these
reports extends into period 3. The first publication of the now widely known
American College of Cardiology (ACC)/American Heart Association (AHA)
guidelines for CHF occurred during this second period of time. The third period
included the last part of the US Carvediolol Heart Failure Trials Program, and one
set of published guidelines. The last period brought another two large trials, one
positive and one negative for beta blockers. Period 4 also produced another
guideline, the first from the Heart Failure Society of America (HFSA), as well as
an observational review of the Studies of Left Ventricular Dysfunction Treatment
(SOLVD) trial, which was originally designed to determine the efficacy of ACE
inhibitors.
Stratification of beta blocker drug mentions by various subgroups are
outlined on table 2-2. Beta blocker mentions in visits by males with CHF occurred
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at nearly twice the rate in women each two year period. The low number of
nonwhite visits during the four periods produced sporadic mention rates. Diabetes
is negatively associated with a beta blocker mention, while hypertension appears to
have a positive association, as would be predicted. Those known to be in an HMO
had nearly twice the rate of drug mentions as those known to not be in an HMO.
Lastly, utilizing logistic regression, we considered the relative importance
of our predictors on beta blocker drug mentions. The OR and 95% CI for our
predictors are found on table 2-3 . In our model for beta blockers, hypertensive
patients (OR 1.177, CI 1.173-1.180), and males (OR 1.945, CI 1.940-1.949) were
positively associated with a drug mention for beta blockers. Diabetic patients (OR
.585, CI .583-.587) and nonwhite patients (OR .690, CI .687-.692) were negatively
associated with a beta blocker drug mention. The period of the visit showed the
strongest association, with visits in period 4 (OR 3.754, CI 3.741-3.766) showing a
dramatic difference from the referent period 1. Periods 2 (OR 1.171 , CI 1.1661.176) and 3 (OR 2.333, CI 2.325-2.341) were between the other two periods.
Angiotensin converting enzyme inhibitors (ACEis)
ACE inhibitor drug mentions have been a recognized part of heart failure
therapy for more than a decade. Their utilization rate shows that they had a
moderate level of usage during the first period (3.4 million drug mentions) as
shown on table 1-6. This rate increased substantially by the fourth period (4.3
million mentions). Drug mention rates in ACEis were large enough to allow for
much more stable RSEs, making for stable estimates in three of the four periods.
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ACE inhibitors present a different case than the other three classes of
medications in that the mortality studies were performed earlier. The first study to
show clinical benefit was published in 1983 [6, 21], and mortality studies followed
shortly[22]. The major studies of the efficacy of ACEis in decreasing mortality
and hospitalizations were completed before our first period of analysis as shown on
table 3-1. The first such study was published in 1987, with a string of later studies
in the early 1990's just prior to our period 1. Due to this earlier clinical study
timing versus our other therapeutic categories, ACEI provide an opportunity to
observe the impact of guidelines without simultaneous changes in research
findings.
Stratification by subgroups does not show the same dramatic subgroup
differences found in beta blockers. Table 3-2 documents that this sample had very
similar drug mention rates by sex, race, hypertension, or HMO coverage. One
exception was found among diabetics. In the last two periods the diabetic mention
rates are nearly double the non-diabetic rates.
The logistic regression model for predictors of ACEI drug mentions is
presented on table 3-3. ACEI prescribing varied between periods yet no strong
predictors were found. In all but the first age category, the ORs were consistently
similar. For sex, race, and hypertensive status, the ORs were very close to one.
Only diabetics had a remarkable association (OR 1.558, CI 1.555-1.561).
Spironolactone

Spironolactone prescribing was difficult to assess due to extremely low
drug mention rates for this drug, which were not statistically stable or reliable. As
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would be expected from table 1-6, few mentions occurred in periods 1-3. There is
a jump in reports in period 4 (to 0.4 million mentions).
There were no large mortality based clinical trials with evidence for
spironolactone use in heart failure until the Randomized Aldactone Evaluation
Study (RALES) [23] which occurred in period 4 as shown on table 4-1. The
resulting weighted visits are stratified on table 4-2, but these numbers represent
very few surveys in all periods, and should be considered with caution. The
logistic regression analysis reveals the dramatic increase in association in period 4
(OR 3.542, CI 3.519-3.564) as compared to period 1. The three older age groups of
the four are negatively associated with spironolactone use (ORs from .510 to.589)
as compared to those younger than 60 year old, which is outlined on table 4-3.

Angiotensin receptor blockers (ARBs)
Drug mentions of ARBs increased from period 1 (173020 weighted drug
mentions), to period 4 (530420 weighted drug mentions) as seen on table 1-6. The
largest change occurred between periods 2 and 3 (360,878 increase in weighted
estimate mentions).
ARBs differ from the previous therapeutic categories in that the evidence
for their use is not based upon direct superiority against placebo, but rather based
upon their equivalence to ACEI. The two studies which measured mortality and
hospitalization, are the ELITE (in period 3) and ELITE II (in period 4) trials as
listed on table 5-1 . These studies did not show statistically significant
improvements in CHF related mortality over ACE inhibitors, but ELITE did show a
slight but significant decrease in all-cause mortality [24]. The first ARB to be
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approved by the FDA was Losartan on April 14th, 1995 which interestingly falls
during period 2 despite already having been available for coding by the NAM CS
during period 1[25] . Two other ARBs were approved during the third period,
Irbesartan on September 30th, 1997, and Candesartan on June 4th, 1998[25] .
Valsartan was not approved until after the 4th period, but was listed by the NAMCS
by period 4.
Differences shown on the stratified sample on table 5-2 are again difficult to
interpret due to the poor reliability and stability of the period estimates due to low
sample size and a low drug mention rate for ARBs. The evaluation of individual
predictors through the logistic regression model is on table 5-3. The dramatic
association with period is shown in period 3 (OR 3.115, CI 3.097-3 .132) and period
4 (OR 3.767, CI 3.788) as compared to period 1.
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DISCUSSION
The eight years of NAM CS data on CHF visits showed statistically
insignificant increases in drug mentions for all four therapeutic categories of
medications which provide benefits in survival or decreased hospitalizations.
Descriptively the mention rates change with surprising similarity to expected
trends, but the lack of reliability of the data precludes statistical inferences to
evaluate the role of chance in our findings. Beta blockers are of particular interest
as the evidence supporting the use of beta blockers mounted during our four study
periods, corresponding with a large increase in drug mention rates observed in the
NAMCS weighted estimates.
For beta blockers, the rate of drug mentions in period 1 is representative of
the drug mention rate when only small trial and supporting theory was available to
influence prescribing. If evidence were the only predictor of beta blocker use,
period 2 would represent the impact of the first large randomized trial which
occurred near the end of period 1. The guidelines directly reflect the prior large
trials, and therefore the 1995 ACC/AHA guidelines released in period 2 discuss
beta blockers cautiously. In the end of period 2 a confirmatory study was
published, and the rate of drug mentions doubled from the initial rate in period 3.
In period 3 and 4, more evidence is published and the drug mention rate increased

further, but still only mentioned in less than 15% of visits with patients with CHF.
There are several reasons why the drug mention rate may be lower than
might be expected. Some comorbidities would make a prescriber hesitant to
prescribe a beta blocker, such as asthma or diabetes due to a relative
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contraindication. Unlike an absolute contraindication which would always be
inappropriate, a relative contraindication would discourage, but permit prescriber
judgments to use the medication with the comorbidity. The NAMCS does limit the
number ofrecorded medications to five in period 1, and six in periods 2-4.
Considering a patient visiting with CHF alone, we would expect many patients to
be treated with an ACEI, diuretic, digoxin, and a beta blocker or spironolactone.
When one diagnosis is associated with four or more medication mentions, it is
likely that a form with space for six drug mentions is not adequate to capture all
medications for all visits. The NCHS plans to increase the number of drug
mentions which can be listed on the survey in coming years[26]. Some
medications are available as combination products, meaning that multiple active
ingredients would be in one tablet. Although captured by the NAM CS, these drug
mentions were not recoded in this study since early testing showed that
combination products accounted for few drug mentions. In this population a
majority of these combination products is for diuretics, which fall outside the scope
of this investigation.
The large RSEs for this study create difficulties when using the NAMCS for
analysis of specific disease states. Even with the frequently used practice of
combining years [20, 27-29], limiting the number of visits by diagnosis quickly
erodes the necessary power when using the approximation equations. Power is also
eroded by the size of the estimate since it is related to the RSE[30]. Analysis of
visits without weighting has very limited utility in describing the prescribing rate in
the United States because the NAMCS is not a random sample, and therefore a

19

report of the raw survey reports of visits is not representative of actual practice.
(

These concerns, taken together, demonstrate the necessity of asking large questions
with this data, or by using SUDAAN to calculate the precise RSEs, which at times
allows for the use of substantially fewer visits than the more conservative estimate
equations.
Increases in drug mentions predicted by period are likely influenced by
several factors in addition to large trials and guidelines. Over the broader period of
1985-1999, Burt was able to show an increase in drug mention rate of 59%. This
rate was largely attributed to the increasing age of the population, new drugs, drug
coverage, and direct to consumer advertising[29]. Increasing age, although
associated with CHF, did not result in an increase in the number of visits, nor was
increasing age associated with a drug mention except with ARBs. New drugs are
also a minor issue in these therapeutic classes, other than the ARBs. Direct to
consumer advertising is also rare in CHF. It is likely other factors are having a
greater effect on CHF than those that are impacting broader prescribing trends.
ACEI mention rates appeared to increase slowly and steadily, although rates
are remarkably low considering the broad agreement to the necessity of their use in
CHF. Several published reports have addressed the inadequate prescribing rate of
these medications in CHF[12-16]. With the majority of the studies on mortality
benefits being prior to our study period, we expect that the guidelines have the
greatest impact during the four periods. We find that period is a significant
predictor of ACEI mentions, as is diabetic status, which is not surprising
considering the great benefit of ACEis in this population[31] . Since ACEis and
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ARBs have similar mechanisms of action and may be viewed by practitioners as
being interchangeable, it is also possible that their trends should be viewed
together, although guidelines and practice do firmly distinguish between the two
classes.
Assessment of spironolactone mention rates provides an opportunity to
determine the impact of one large randomized trial. While some prescribing of
spironolactone may be attributed to its diuretic properties for symptomatic relief,
we do find that the mention rate increased dramatically, but not statistically
significantly, after publication of the RALES trial. The spironolactone analysis is
statistically limited by its low drug mention rate, which did not allow for a reliable
or precise estimate.
The increase in ARB prescribing is most pronounced in period 3. During
this period we do have the first trial showing equivalence of ARBs to ACEis.
During the third period, irbesartan and candesartan were approved, joining losartan,
which was the only approved ARB during the previous period. Unlike the other
therapeutic categories, guidelines discourage the use of ARBs in preference to
ACEis, except where latter is not tolerated due to side effects [6, 8, 9, 32, 33].
These agents are more recent developments, and although not generally marketed
directly to consumers, they certainly do have substantial sales force support from
their respective manufacturers. Since the ARBs did not yet have FDA approval for
the treatment of CHF during this period, this marketing influence should be a minor
concern since the FDA prohibits marketing unapproved indications.
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Although in this study we were able to report rates of drug mentions which
corresponded with the guidance provided by the most important studies, review
articles and other smaller influences can not be accounted for. The guideline
update from the ACC/AHA for CHF in 2001 also falls outside the focus of this
study. Further studies in the reasons behind the rates of adoption of lifesaving
medication, and effective interventions to ensure appropriate use are needed.
We conclude from our collected information, and statistical analyses that
the NAM CS demonstrated marked trends, but this study was inadequately powered
to establish statistical significance. The trends showed dramatic increases in drug
mentions which corresponded temporally with major published evidence. Beta
blocker trends suggested that two studies were necessary to increase prescribing,
perhaps due to prior theory which suggested the class to be contraindicated.
Spironolactone, which unlike beta blockers would not have contraindication
concerns, increased dramatically after only one large study. This suggesting that
some prescribers are reacting quickly to new high quality evidence, but further
research utilizing other data sets may offer more reliable answers in time.
Although power limitations inherent to the NAMCS limited statistical
inferences, the strengths of the NAMCS should not be ignored. The NAMCS is
limited by resources, versatility, and anonymity. Federal resources for the NAM CS
are limited, and the survey instrument attempts to capture an enormous number of
topics. Physician participation is voluntary, and therefore anonymity is necessary
for high response rates, which limits the data that can be released. The strengths of
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the NAMCS include persistence over multiple years, national coverage, and
extensive details about visits.
Future research should be directed to establishing the degree to which these
trends are statistically significant, which would require either more precise methods
(notably the use of SUDAAN), or a different data source. Other data sources may
involve primary data collection, or the utilization of regional data. It is important
that research also be directed toward establishing optimal prescribing rates, which
match the evidence to allow for benchmarking by individual health organizations.
This information is necessary to evaluate the adequacy of the current evidence
dissemination system.
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Table 1-1: NAM CS Survey Response Rates by Year
Year

Physicians in

Percent

Sc~e

Re.E_orti~

1993
1994
1995
1996
1997
1998
1999
2000

2464
2426
2587
2142
1801
1806
1728
2049

73.0%
70.2%
72.8%
70.0%
69.2%
67.9%
62.9%
67.7%
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Total Surveys
Returned

35,978
33,598
36,875
29,805
24,715
23,339
20,760
27,369

/

Table 1-2: ICD-9 codes used to identify sample and comorbidity based
subgroups
Heart Failure
428.0
428.1
428.9

Asthma
493.00
493.01
493.10
493.11
493.20
493.21
493.90
493.91

Diabetes
250*

Hy__]2_ertension
401*
402.00
402.10
402.90
403*
404.0
404.2
405*
U1

..

*mcludes all 4U1 and 5 digit subclass1ficat10ns
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Table 1-3: List of generic names of medications captured within each
. cate_g_ory use d to ..£.fevent morta1ity
· an d h o~ta
. i izat10n
· . m
. CHF
th erapeutlc
Angiotensin
Converting
Angiotensin
II Receptor
Spironolactone
Beta Blockers
Enzyme Inhibitor
Blockers (ARB)
(ACEI)

Atenolol
Bisoprolol
Carvedilol
Labetalol
Metoprolol
Nadolol
Propranolol
Sotalol

Benazepril
Captopril
Enalapril
Fosinopril
Lisinopril
Quinapril
Ramipril
Trandolapril

Spironolactone
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Candesartan
Irbesartan
Losartan
Valsartan

(

Table 1-4 Weighted frequency and percent occurrence of demographic
ch arac t enst1cs of CHF VlSl
. 't S 1Il
. NAMCS fior _years 1993 -2000
Weighted*
Percent of
Characteristic
Frequency
weighted* visits
n = 47,188,507 within subgrou..£_s
Period
12,329,611
26.1
1993-94
1995-96
12,212,841
25.9
1997-98
11,296,468
23.9
11,349,587
24.1
1999-2000
Sex
24,491,634
Female
51.9
22,696,873
48.1
Male
A_g_e
0-59
5,397,099
11.5
60-69
8,481,791
18.0
70-79
15,665,945
33.2
80+
17,643,672
37.3
Race
41,179,969
White
87.3
4,957,055
10.5
Black
Other
1,051,483
2.2
Dia_g_nosed diabetes visit
Non-diabetic
40,599,823
86.0
Diabetic
6,588,684
14.0
Di~nosed asthma visit
Non-asthmatic
46,587,112
98.7
Asthmatic
601,395
1.3
Dia_g_nosed b_.Il!_ertension visit
N on-hl'.:Q_ertensi ve
38,694,590
82.0
Hypertensive
8,493,917
18.0
Visit _p_a_r.ment
Private insurance
6,998,833
14.8
26,081,485
Medicare
55.3
Medicaid
1,786,835
3.8
Other
590,897
1.2
Blank or unknown
10,725,545
22.8
HMO status
HMO _EJ.an
6,877,066
14.6
Non-HMO 2_lan
38,379,787
81.3
Blank or unknown
1,931,654
4.1
*Weighted values represent the sample adjusted to represent national visit
characteristics

27

(

Table 1-5 Weighted frequency of CHF visits and aggregate
multiyear relative standard error (RSE) of visits 1993-2000 by year
Visit period
1993-94
1995-96
1997-98
1999-2000

Number of CHF
visits•

12,329,611
12,212,841
11,296,468
11,349,587

Multi-year relative
standard error for
CHF visits

95% confidence intervals for
number of CHF visits per 2
~ar_p_eriod

7.04
11,461,607-13,197,615
11,245,584-13,180,098
7.92
10.12
10, 153,266-12,439,670
10,208,954-12,490,220
10.05
*weighted number ofv1sits over period
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Table 1-6 Weighted frequency and percent of medication mention rates in
CHF from 1993-2000 by year
Beta Blockers
1993-94
1995-96
I 997-98
1999-2000
ACEI
1993-94
1995-96
1997-98
1999-2000

Number of visits with one
or more dr~ mention

Relative Standard Error for
number of mentions

Percent of visits with one
dru_g_ mention

487,601 *
581,175*
1,052,052*
1,617,562*

54.89
48.37
58.11
40.21

4.0t
4.8t
9.3t
14.3t

3,398,254
3,870,147
3,341,295*
4,286,231

18.89
19.96
30.13*
26.68

27.6t
31.7_1_
29.6_1_
37.8t

126,965*
97,899*
158,048*
414,960*

136.74
135.99
160.45
68.56

1.0t
0.8t
l .4t
3.7_1_

173,020*
137,381*
498,259*
530,420*

88.55
102.95
82.94
63.76

1.41_
1.1_1_
4.4t
4.7t

~ronolactone

1993-94
1995-96
1997-98
1999-2000
ARBs
1993-94
1995-96
1997-98
1999-2000

(

*Value does not meet standard of reliability or precision based upon a RSE > 30
tValue does not meet standard of reliability or precision based upon a denominator RSE 2'.5 or a
numerator and denominator RSE 2'. 10
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Table 2-1 Summary of major trials using beta blockers in CHF which measured
mortality, hospitalizations, or a combined mortality-hospitalization effect, and
influential guidelines 1993-2000
Study/guideline title

Journal reference

Period

Findings

Cardiac Insufficiency Bisoprolol Study

Circulation. 1994
Oct;90(4): 1765-73

1

ACC/AHA Guidelines for the Evaluation
and Management of Chronic Heart
Failure in the Adult

Circulation 1995 Nov
1;92(9):2764-84

2

The US Carvedilol Heart Failure Trials
Program

N Engl J Med 1996 May
23 ;334(21):1349-55

2

Mortality .J.Hospitalization

Prospective Randomized Evaluation of
Carvedilol on Symptoms and Exercise*

Circulation 1996 Dec
1;94(11 ) :2793-9

2

Mortality

Multicenter Oral Carvedilol Heart Failure
Assessment Study*

Circulation 1996 Dec
1;94(11 ) :2807-16

2

Mortality .J.Hospitalizations

Heart Failure guidelines of the European
Society of Cardiology

Eur Heart J 1997
May; 18(5):736-53

3

NA

Study of the Safety and Efficacy of
Carvedilol in Severe Heart Failure*

J Card Fail 1997
Sep;3(3) : 173-9

3

Insufficient power
to evaluate

Cardiac Insufficiency Bisoprolol Study II

Lancet 1999 Jan
2;353(9146):9-13

4

Mortality

Metoprolol CR/XL Randomized
Intervention Trial in Heart Failure

Lancet 1999 Jun
l 2;353(9169):2001-7

4

Mortality .J.Hospitalizations

HFSA Guidelines for the Management of
Patients with Heart Failure Caused by
Left Ventricular Systolic Dysfunction Pharmacological Approaches.

The Journal of Cardiac
Failure, 1999;5 :357-382

4

Retrospective Analysis of Studies of Left
Ventricular Dysfunction Treatment Trial

J Am Coll Cardiol.
1999; 33 :916-923

4

Mortality

.J.-

Beta-Blocker Survival Trial

Paper presented at: 1999
Scientific Sessions of
the AHA; Nov. 7-10,
1999; Atlanta, GA

4

Mortality

1'

Mortality .J.Hospitalization

.J.-

NA

.J.-

.J..J.-

.J..J.-

NA

*indicates component study of US Carvedilol HF Trials Program
NA = Not a licable
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Table 2-2 Weighted rates of one or more drug mentions in CHF for beta blocker
stratified by subgroup visit demographics
N um b er o f vts1ts
.. b~atlent

~e

. h a b eta bl oc k ers mention.
an d_2'._ear, an d_E:rcent o f the~ven n wit

0-59
Year

1993-94
1995-96
1997-98
1999-2000

n

1229933
1223361
1255262
1688543

60-69
%
10.9
4.1%
8.7%
16.6%

%
2.4%
2.9%
7.5%
21.4%

n

2069616
2024943
2055364
2331868

70-79
N

4016916
4633977
3867993
3147059

80+

%
4.1%
4.4%
6.8%
12.4%

N

5013146
4330560
4117849
4182117

%
2.8%
6.2%
12.7%
10.7%

N um b er o f vts1ts
. . b~sex an d ~ar, an d_E_ercent o f the~ven n wit
. h a b eta bl oc ker mention
Female
Male
Year
n
%
n
%

1993-94
1995-96
1997-98
1999-2000

7124629
6282195
5562697
5522113

3.2
2.4
5.6
11.3

5204982
5930646
5733771
5827474

5.0
7.2
12.9
17.0

N umb er o f v1s1ts
.. b~race an d~ar, an d_E_ercent o f the~ven n wit. h a b eta bl oc k er ment10n
White
Non-white
Year
n
%
n
%

1993-94
1995-96
1997-98
1999-2000

10733051
10776537
9926163
9744218

3.4
5.3
8.9
15.9

1596560
1436304
1370305
1605369

7.7
.6
12.3
4.2

Number of visits by recorded diabetic diagnosis and year, and percent of the given n with a beta blocker
mention
Non-diabetic
Diabetic
Year
n
%
n
%

1993-94
1995-96
1997-98
1999-2000

10772854
10535885
9727608
9563476

4.5
5.4
9.0
15.3

1556757
1676956
1568860
1786111

0
0.5
11.3
8.8

Number of visits by recorded hypertensive diagnosis and year, and percent of the given n with a beta blocker
mention
Hypertensive
Non-h_i'Il_ertensive
Year
n
%
n
%

1993-94
1995-96
1997-98
1999-2000

10301868
10349848
8888661
9154213

3.7
5.2
9.1
13.4

2027743
1862993
2407807
2195374

5.0
2.4
10.2
17.8

N um b er o f v1s1ts
. . b~ HMO status an d_2'._ear, an d_E_ercent o f the _g_iven n w1"th a b eta bl ocker men ti on
HMOjl_lan
Non-HMO_E}an
Year
n
%
n
%

1993-94
1995-96
1997-98
1999-2000

1401535
1916046
1645452
1914033

6.1
7.3
17.0
24.3

31

10928076
10296795
9176491
7978425

3.7
4.3
7.4
11.4

(

Table 2-3 Logistic regression model for identifying significant predictors of beta
blocker drug mentions in CHF visits
Predictor Variables
Period 1, 1993-94 (referent)
Period 2, 1995-96
Period 3, 1997-98
Period 4, 1999-2000
Age 0-59 (referent)
Age 60-69
Age 70-79
Age 80+
Sex female (referent)
Sex male
Race White (referent)
Race Non-white
Non-diabetic (referent)
Diabetic
Non-hypertensive (referent)
Hypertensive

Odds Ratio

95% Confidence Interval

1.171
2.333
3.754

1.166- 1.176
2.325 - 2.341
3.741 - 3.766

.763
.580
.728

.761 - .766
.578 - .582
.725 - .730

1.945

1.940 - 1.949

.690

.687 - .692

.585

.583 - .587

1.177

1.173 - 1.180
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Table 3-1 Summary of major trials using ACE inhibitors in CHF which measured
mortality, hospitalizations, or a combined mortality-hospitalization effect, and
influential guidelines 1987-2000
Study/guideline title

Effects of enalapril on mortality in
severe congestive heart failure. Results
of the Cooperative North Scandinavian
Enalapril Survival Study
(CONSENSUS). The CONSENSUS
Trial Study Group .
Effect of enalapril on survival in patients
with reduced left ventricular ejection
fractions and congestive heart failure.
The SOLVD Investigators.
A comparison of enalapril with
hydralazine-isosorbide dinitrate in the
treatment of chronic congestive heart
failure.
Effect of captopril on mortality and
morbidity in patients with left ventricular
dysfunction after myocardial infarction.
Results of the survival and ventricular
enlargement trial. The SAVE
Investigators.
Effect of enalapril on mortality and the
development of heart failure in
asymptomatic patients with reduced left
ventricular ejection fractions. The
SOLVD Investigators.

Journal reference

N Engl J Med 1987 Jun

4;316(23): 1429-35

N Engl J Med 1991 Aug
I ;325(5):293-302

N Engl J Med 1991 Aug

I ;325(5):303-10

N Engl J Med 1992 Sep

3;327(10):669-77

N Engl J Med 1992 Sep

3;327(10):685-91

Period

Findings

NA

Mortality""

NA

Mortality""
Hospitalization ""

NA

Mortality""

NA

Mortality""

NA

Mortality""
Hospitalization ""

ACC/AHA Guidelines for the Evaluation
and Management of Chronic Heart
Failure in the Adult

Circulation 1995 Nov
I ;92(9):2764-84

2

NA

Heart Failure guidelines of the
European Society of Cardiology

Eur Heart J 1997
May; 18(5):736-53

3

NA

HFSA Guidelines for the Management
of Patients with Heart Failure Caused
by Left Ventricular Systolic Dysfunction
- Pharmacological Approaches.

The Journal of Cardiac
Failure, I 999;5:357-382

4

NA

NA = Not a
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licable

Table 3-2 Weighted rates of one or more drug mentions in CHF for ACEis
stratified by subgroup visit demographics
N um b er o f v1s1ts
.. b~t1ent

d

~an ~ar,

an d_E_ercent o f t he_.&!ven n wit. h an ACE! mention.

0-59
Year
1993-94
1995-96
1997-98
1999-2000

60-69

n

%

n

1229933
1223361
1255262
1688543

41.7
35.9
28.4
38.0

2069616
2024943
2055364
2331868

70-79
%
30.1
23.9
29.4
44.5

80+

N

%

N

4016916
4633977
3867993
3147059

26.1
29.7
35.2
27.8

5013146
4330560
4117849
4182117

%
24.2
36.3
24.7
41.4

N um b er o f v1s1ts
.. b~sex an dy_ear, an d_E_ercent o f t he _&!Ven n wit. h an ACEI mention

Year
1993-94
1995-96
1997-98
1999-2000

Female
n
7124629
6282195
5562697
5522113

Male
%
26.2
32.5
30.7
38.8

N
5204982
5930646
5733771
5827474

%
29.4
30.9
28 .5
36.8

N um b er o f v1s1ts
.. b~race an dy_ear, an d_E_ercent o f the _&!Ven n wit
. h an ACEI mention

Whjte
Year
1993-94
1995-96
1997-98
1999-2000

n
10733051
10776537
9926163
9744218

%
27 .0
32.2
29.l
37.5

Non-white
%
n
31.6
1596560
1436304
27.9
1370305
33.2
1605369
39.4

. d'1~nos1s an d~ar, an d2_ercent o f the_.&!ven n with an ACEI mention
N um b er o f v1s1ts
.. b~ record ed d'ia bet1c

Year
1993-94
1995-96
1997-98
1999-2000

Non-diabetic
n
%
10772854
26.7
10535885
32.6
9727608
27.6
9563476
33.7

Diabetic
n
1556757
1676956
1568860
1786111

%
33 .2
25 .7
42.1
59.8

Number of visits by recorded hypertensive diagnosis and year, and percent of the given n with an ACE!
mention

Year
1993-94
1995-96
1997-98
1999-2000

Non-h_l'2_ertensive
n
%
10301868
27.7
10349848
31.5
8888661
28.1
9154213
37.9

HJ:'2_ertensive
n
%
2027743
27.0
1862993
33.0
2407807
35 .1
2195374
37.2

N umb er o f v1s1ts
. . b'J'j_ HMO status an dy_ear, an d_E_ercent o f the_s!ven n wit
. h an ACEI mention

Year
1993-94
1995-96
1997-98
1999-2000

HM0_£1an
n
%
1401535
34.9
1916046
32.9
1645452
34.l
1914033
36.9

34

Non-HMO_E_lan
n
%
10928076
26.6
10296795
31.5
9176491
27.8
7978425
36.6

(

Table 3-3 Logistic regression model for identifying significant predictors of ACEI
drug mentions in CHF visits
Predictor Variables
Period 1, 1993-94 (referent)
Period 2, 1995-96
Period 3, 1997-98
Period 4, 1999-2000
Age 0-59 (referent)
Age 60-69
Age 70-79
Age 80+
Sex female (referent)
Sex male
Race White (referent)
Race Non-white
Non-diabetic (referent)
Diabetic
Non-hypertensive (referent)
Hypertensive

Odds Ratio

95% Confidence Interval

1.221
1.094
1.557

1.219-1.223
1.092-1.096
1.554-1.559

.852
.812
.868

.850-.854
.811-.814
.866-.870

1.010

1.009-1.012

1.051

1.049-1.053

1.558

1.555-1.561

1.087

1.086-1.089
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Table 4-1 Summary of major trials using spironolactone in CHF which measured
mortality, hospitalizations, or a combined mortality-hospitalization effect, and
influential guidelines 1993-2000
Study/guideline title

ACC/AHA Guidelines for the Evaluation
and Management of Chronic Heart
Failure in the Adult

Journal reference
Circulation 1995 Nov

I ;92(9):2764-84

Period

Findings

2

NA

Heart Failure guidelines of the
European Society of Cardiology

Eur Heart J 1997
May; 18(5):736-53

3

NA

HFSA Guidelines for the Management
of Patients with Heart Failure Caused
by Left Ventricular Systolic Dysfunction
- Pharmacological Approaches.

The Journal of Cardiac
Failure, l 999;5:357-382

4

NA

The effect of spironolactone on
morbidity and mortality in patients with
severe heart failure . Randomized
Aldactone Evaluation Study
Investigators.

N Engl J Med 1999 Sep

2;341(I0):709-17

4

Mortality .J..
Hospitalizations
NA =Not a
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.J..
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Table 4-2 Weighted rates of one or more drug mentions in CHF for spironolactone
stratified by subgroup visit demographics
N umb er o f v1s1ts
.. b~at1ent

~e

an d_}'._ear, an d _JJ_ercent o fh
t e_given n wit' h a

0-59
Year

1993-94
1995-96
1997-98
1999-2000

60-69
%

n

%

N

%

N

%

1229933
1223361
1255262
1688543

0.1
1.2
0.5
9.0

2069616
2024943
2055364
2331868

2.3
0.3
2.3
1.0

4016916
4633977
3867993
3147059

0
1.0
2.7
2.8

5013146
4330560
4117849
4182117

1.5
0.7
0
3.6

actone mention
Male

~rono

Female

1993-94
1995-96
1997-98
1999-2000

80+

n

N um ber o f v1s1ts
.. b~sex an d ~ar, an d_E_ercent o fh
t e_given n wit' h a
Year

actone mention.

~rono

70-79

n

%

n

%

7124629
6282195
5562697
5522113

1.3
1.2
0.7
4.0

5204982
5930646
5733771
5827474

0.7
0.4
2.1
3.3

N um b er o f v1s1ts
.. b~race an d _year, an d_E_ercent o fh
'h a ~rono actone mention
t e_given n wit
White
Non-white
Year
n
%
n
%

1993-94
1995-96
1997-98
1999-2000

10733051
10776537
9926163
9744218

1.2
0.6
1.6
3.2

1596560
1436304
1370305
1605369

0.1
2.6
0
6.4

Number of visits by recorded diabetic diagnosis and year, and percent of the given n with a spironolactone
mention
Non-diabetic
Diabetic
Year
%
n
n
%

1993-94
1995-96
1997-98
1999-2000

10772854
10535885
9727608
9563476

1.2
0.9
1.6
3.3

1556757
1676956
1568860
1786111

0
0
0
5.5

Number of visits by recorded hypertensive diagnosis and year, and percent of the given n w ith a
sE!rono
.
Iactone mention
.
Non-~ertensive
H_.YE._ertensive
Year
%
n
n
%

1993-94
1995-96
1997-98
1999-2000

10301868
10349848
8888661
9154213

0.8
0.9
0.7
3.8

2027743
1862993
2407807
2195374

2.4
0.5
3.9
3.2

N um b er o f v1s1ts
.. b~ HMO s t a t us an d_}'._ear, an d_E_ercen t o f th e_given n w1'th a ~rono actone m en ti on
HMO_Q(an
Non-HMO~an
Year
n
%
n
%

1993-94
1995-96
1997-98
1999-2000

1401535
1916046
1645452
1914033

0
0
0
0
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10928076
10296795
9176491
7978425

1.2
1.0
1.7

3.6

(

Table 4-3 Logistic regression model for identifying significant predictors of
spironolactone drug mentions in CHF visits
Predictor Variables
Period 1, 1993-94 (referent)
Period 2, 1995-96
Period 3, 1997-98
Period 4, 1999-2000
Age 0-59 (referent)
Age 60-69
Age 70-79
Age 80+
Sex female (referent)
Sex male
Race White (referent)
Race Non-white
Non-diabetic (referent)
Diabetic
Non-hypertensive (referent)
Hypertensive

Odds Ratio

95% Confidence Interval

.792
1.347
3.542

.786-.799
1.337-1.357
3.519-3 .564

.510
.589
.537

.506-.513
.586-.593
.533-.540

.884

.880-.888

1.158

1.151-1.165

.780

.775-.786

1.551

1.543-1.559
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Table 5-1 Summary of major trials using ARBs in CHF which measured
mortality, hospitalizations, or a combined mortality-hospitalization effect, and
influential guidelines 1993-2000
Study/guideline title
ACC/AHA Guidelines for the Evaluation
and Management of Chronic Heart
Failure in the Adult
Randomized trial of losartan versus
captopril in patients over 65 with heart
failure (Evaluation of Losartan in the
Elderly Study, ELITE)

Journal reference
Circulation 1995 Nov

I ;92(9):2764-84

Lancet 1997 Mar

I 5;349(9054):747-52

Period

Findings

2

NA

3

CHF mortality no
different from
ACEI, but all
cause mortality "-'

Heart Failure guidelines of the
European Society of Cardiology

Eur Heart J 1997
May; 18(5):736-53

3

NA

HFSA Guidelines for the Management
of Patients with Heart Failure Caused by
Left Ventricular Systolic Dysfunction Pharmacological Approaches.

The Journal of Cardiac
Failure, 1999;5 :357-382

4

NA

4

Mortality no
different from
ACEI

Effect of losartan compared with
captopril on mortality in patients with
symptomatic heart failure : randomized
trial--the Losartan Heart Failure Survival
Study ELITE II.

Lancet 2000 May

6;355(9215): 1582-7

NA =Not applicable
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Table 5-2 Weighted rates of one or more drug mentions in CHF for ARBs
stratified by subgroup visit demographics
N um ber o f v1s1ts
.. b~t1ent

~an d~ar,

an d__.E_ercent ofh
t e~ven n wit"h an ARB mention.

0-59
Year

1993-94
1995-96
1997-98
1999-2000

60-69

70-79

80+

n

%

n

%

N

%

N

%

1229933
1223361
1255262
1688543

2.8
1.8
2.0
2.7

2069616
2024943
2055364
2331868

0
2.4
3.6
1.8

4016916
4633977
3867993
3147059

3.0
0.8
7.2
7.9

5013146
4330560
4117849
4182117

0.3
0.7
2.9
4.6

N um ber of v1s1ts
.. b~sex an d1ear, an d_.12._ercent ofh
t e_&!Ven n wit"h an ARB mention

Female
Year

1993-94
1995-96
1997-98
1999-2000

Male

n

%

n

%

7124629
6282195
5562697
5522113

1.8
1.2
5.0
5.4

5204982
5930646
5733771
5827474

0.9
1.0
3.8
4.0

.
N um ber o f v1s1ts
.. b~race an d_}'ear, an d_.12._ercent of t he_&!Ven
n wit. h an ARB mention

Non-white

White
Year

1993-94
1995-96
1997-98
1999-2000

n

%

n

%

10733051
10776537
9926163
9744218

1.0

1596560
1436304
1370305
1605369

4.4

1.1

3.8
5.0

1.3

8.9
2.8

N um ber of v1s1ts
.. b~recorded d"1abet1c
. d"1~os1s an d1ear, an d2_ercent of the_.s!ven n wit· h an ARB mention

Year

1993-94
1995-96
1997-98
1999-2000

n

Non-diabetic
%

10772854
10535885
9727608
9563476

1.5
1.3
5.0
5.0

Diabetic
n

1556757
1676956
1568860
1786111

%
1.1

0
0.7
2.7

Number of visits by recorded hypertensive diagnosis and year, and percent of the given n with an ARB
mention
Non-~ertensive
H_i'.E_ertensive
Year
n
%
n
%

1993-94
1995-96
1997-98
1999-2000

10301868
10349848
8888661
9154213

0.3
0.9
3.9
4.1

2027743
1862993
2407807
2195374

7.2
2.5
6.3
7.1

.h an ARB mention
N um b er o f v1s1ts
.. b~HMO status an d1ear, an d_.12._ercent of the_&!Ven n wit

HMO_E_lan
Year

1993-94
1995-96
1997-98
1999-2000

n

%

1401535
1916046
1645452
1914033

0
1.2
3.7
3.0
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Non-HMO_E!an
n
%

10928076
10296795
9176491
7978425

1.6
1.1

4.7
5.3

Table 5-3 Logistic regression model for identifying significant predictors of ARB
drug mentions in CHF visits
Predictor Variables
Period 1, 1993-94 (referent)
Period 2, 1995-96
Period 3, 1997-98
Period 4, 1999-2000
Age 0-59 (referent)
Age 60-69
Age 70-79
Age 80+
Sex female (referent)
Sex male
Race White (referent)
Race Non-white
Non-diabetic (referent)
Diabetic
Non-hypertensive (referent)
Hypertensive

Odds Ratio

95% Confidence Interval

.794
3.115
3.767

.788-.799
3.097-3 .132
3.746-3.788

.991
2.275
1.058

.984-.999
2.260-2.289
1.050-1.065

.673

.670-.675

1.259

1.253-1.264

.375

.373-.378

2.512

2.503-2.521
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Appendix A: List of Definitions
ICD-9 = The International Classification of Diseases Revision 9 is a coding system
which enables payers and providers of health services to efficiently
communicate diagnoses.
NAMCS =The National Ambulatory Medical Care Survey is an annually
performed national probability survey which records an extensive and
varied list of characteristics regarding visits to physicians in the United
States. The survey is designed to describe the use of ambulatory services in
the US.
NCHS =The National Center for Health Statistics is a branch of the Centers for
Disease Control (CDC), which falls under the U.S. Department of Health
and Human Services (HHS). This department provides key health
surveillance information which is utilized by a diverse set of stakeholders to
identify issues and direct policy.
RSE

= The Relative Standard Error is used to measure the reliability and
precision of a sample by capturing the degree sampling variability and
nonsystematic biases present in the sample. The RSE can be translated to a
confidence interval by multiplying the RSE by the estimate to obtain the
standard error. There is a 95% confidence that the true value lies within
twice the standard error of the estimated value.

SPSS =The Statistical Package for the Social Sciences is a analytical software
product with a broad statistical capabilities to aid in decision making. It
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utilizes a graphical user interface, which often facilitates intuitive data
manipulation and analysis.
SUDAAN = A statistical software package, formerly named Survey Data Analysis,
which specializes in the analysis of cluster-correlated data. SUDAAN takes
into account the complex sampling design of the NAMCS , eliminating the
need of less powerful approximation equations.
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Appendix B: Excerpt from NCHS internal memo on RSE estimation for aggregate
measures using multi year NAM CS data
by I.M. Shimizu,
December 9, 1993

Sampling Errors for Estimates Based on Multi-Years ofNAMCS Data
This document presents procedures which one may use to approximate sampling
errors of estimates based on NAM CS data collected across multiple years.
1. Variance of estimated aggregate across years
For discussion purposes, let:
Yi = estimated total based on data from the individual year i.
k

Y=L:t
data.

be the estimated aggregate NAMCS total across k years ofNAMCS

i- 1

F
be that year in which NAM CS had the fewest number of responding
physicians among the years included in the study (1 :SF :S k) . (Table 1 gives
numbers ofrespondents for 1989-92.)
Var (Yr)= Variance ofYr derived from the appropriate NAMCS error curve for
year F.
Then the variance of Y may be approximated with
V~(Y) =Var (Yr)[k(2/I- 1) - 2/1+2],

where

I=

0.9 for statistic for all physicians (without regard to specialty), for
pediatricians only, or for OB/GYNs only.
1 for statistics for internal medicine specialty only.
0.8 for all other physician groups.

The approximation formulated in this equation is believed to be conservative. That
is, the approximation should overstate, rather than understate, the variance
for most multi-year aggregate estimates based on NAMCS data.
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Appendix C: Excerpt from NCHS internal memo on RSE estimation for
proportions using multiyear NAM CS data
by David A. Woodwell,
November 4, 2002
Question: Is there a recommended procedure for estimating the variance of a
proportion when combining several years of NAM CS data?
Response:
FIRST SOME NOTATION:
Let x(i) and y(i) be binomial characteristics of interest for the ith sample unit.
x(i) = 1 or 0 and y(i) = 0 or 1.
Let X =sum ofx(i) over the sample units. Let Y =sum of y(i) over the sample
units.
LetR=X/Y.

If x(i) = 1 only when y(i) = 1, then R = X!Y is a proportion [the x(i)=l units are a
subset of the y(i)=l units]
THEN
When both X and Y are estimated from the same survey, then a crude
approximation typically used by NCHS analysts for the RSE of the proportion is:
RSE(R) = RSE(XIY) =square root of [square RSE(X) - square RSE(Y)]
provided RSE(Y) < 0.05 or both RSE(X) <0.10 AND RSE(Y) < 0.10. If the
conditions fail, your estimate is not stable. The RSE(X) and RSE(Y) are
approximated in the same way as any other multi-year aggregate statistic. The A
and B parameters of error curves for X and Y should be taken from the same year
to prevent negative results.

If the X and Y are estimated from different surveys, then
RSE(R) = RSE(XIY) =square root of [square RSE(X) +square RSE(Y)],
again provided the conditions are satisfied.
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